The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement

BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX) today announced an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.

The agreement between Crown Bioscience, a global technology platform for Oncology, and Cardiovascular and Metabolic Disease, and JAX, a non-profit biomedical research institution and worldwide provider of high-quality research models and services, facilitates the shared objective of both organizations; to accelerate and advance the rate of pre-clinical research and discovery.

As part of the agreement: CrownBio will advance the use of JAX^® Mice in client research studies. CrownBio will increase the utilization and improve access of JAX research models, including humanized NSG™ and NSG™-SGM3, thus advancing the research and translational efforts of organizations globally.

JAX research scientists will have select access to CrownBio’s pre-clinical contract laboratory services, providing JAX scientists with additional resources and facilities in which to continue the search for cures for cancer and other diseases.

“The agreement with JAX heralds a significant step forward for Oncology and Immuno-Oncology pre-clinical research,” said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience.  “The utilization of JAX’s scientific-leading humanized and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development.”

Research teams at JAX, focused on understanding the genetic and biochemical signatures that can be targeted by next-generation precision medicines, will immediately begin leveraging CrownBio’s vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.

“The Jackson Laboratory’s mission is to empower the global biomedical community in our shared quest to improve human health.  By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services,” stated Auro Nair, Ph.D., President of JAX^® Mice, Clinical & Research Services.  “Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilizing the world’s largest collection of PDX and cell-line models and services from CrownBio.”

About Crown Bioscience

CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology and cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.

About The Jackson Laboratory

The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,900 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.

JAX Contact:
Dr. Charles Miller
Director of Marketing & Customer Support
207-288-6895 [email protected]

Crown Bioscience Media Contact:
Gavin Cooper
Executive Director Marketing
[email protected]